ORs and 95% CIs of breast cancer by quartile of total 12-h overnight aMT6s output [aMT6s concentration (ng/mL) multiplied with 12-h volume in mL]
Group and parameter | Quartile | ||||
---|---|---|---|---|---|
1 | 2 | 3 | 4 | Ptrend* | |
Urinary aMT6s output/12 h (μg) | <10.1 | 10.1-14.6 | 14.7-20.5 | ≥20.6 | |
No. of case patients/no. of control subjects | 39/170 | 34/171 | 55/172 | 52/170 | |
Invasive and in situ breast cancer cases | |||||
Simple OR* | 1.00 (Reference) | 0.91 (0.54-1.53) | 1.50 (0.92-2.45) | 1.53 (0.91-2.56) | 0.01 |
Multivariate OR† | 1.00 (Reference) | 0.88 (0.51-1.50) | 1.43 (0.85-2.42) | 1.43 (0.83-2.45) | 0.03 |
Excluding current smokers | |||||
No. of case patients/no. of control subjects | 32/96 | 27/107 | 44/106 | 41/114 | |
Simple OR† | 1.00 (Reference) | 0.75 (0.41-1.36) | 1.24 (0.70-2.20) | 1.16 (0.63-2.15) | 0.19 |
Multivariate OR‡ | 1.00 (Reference) | 0.72 (0.38-1.38) | 1.11 (0.59-2.08) | 1.00 (0.52-1.94) | 0.29 |
Multivariate lagtime analyses among nonsmokers | |||||
No. of case patients/no. of control subjects | 5/35 | 4/29 | 8/33 | 11/35 | |
Multivariate OR‡ among women diagnosed within 3 y from urine collection | 1.00 (Reference) | 0.90 (0.09-8.75) | 1.88 (0.23-15.3) | 14.8 (1.39-157) | 0.03 |
No. of case patients/no. of control subjects | 30/73 | 24/82 | 41/81 | 35/89 | |
Multivariate OR‡ 1 y lag time | 1.00 (Reference) | 0.61 (0.30-1.23) | 1.07 (0.54-2.12) | 0.90 (0.45-1.82) | 0.40 |
No. of case patients/no. of control subjects | 28/65 | 24/79 | 38/75 | 30/83 | |
Multivariate OR‡ 2 y lagtime | 1.00 (Reference) | 0.58 (0.28-1.19) | 0.95 (0.47-1.94) | 0.68 (0.32-1.44) | 0.63 |
No. of case patients/no. of control subjects | 27/61 | 23/78 | 36/73 | 30/79 | |
Multivariate OR‡ 3 y lagtime | 1.00 (Reference) | 0.51 (0.24-1.08) | 0.87 (0.42-1.82) | 0.69 (0.32-1.48) | 0.52 |
No. of case patients/no. of control subjects | 24/53 | 19/73 | 33/67 | 28/68 | |
Multivariate OR‡ 4 y lag time | 1.00 (Reference) | 0.41 (0.18-0.92) | 0.76 (0.34-1.66) | 0.61 (0.26-1.39) | 0.80 |
No. of case patients/no. of control subjects | 23/52 | 19/64 | 28/65 | 27/62 | |
Multivariate OR‡ 5 y lag time | 1.00 (Reference) | 0.47 (0.20-1.09) | 0.66 (0.29-1.48) | 0.66 (0.28-1.54) | 0.93 |
No. of case patients/no. of control subjects | 20/44 | 17/57 | 25/57 | 23/51 | |
Multivariate OR‡ 6 y lag time | 1.00 (Reference) | 0.46 (0.18-1.14) | 0.68 (0.28-1.64) | 0.75 (0.29-1.92) | 0.79 |
No. of case patients/no. of control subjects | 19/40 | 16/51 | 22/47 | 16/46 | |
Multivariate OR‡ 7 y lag time | 1.00 (Reference) | 0.43 (0.16-1.17) | 0.53 (0.19-1.47) | 0.38 (0.13-1.11) | 0.13 |
No. of case patients/no. of control subjects | 18/31 | 15/46 | 18/39 | 12/36 | |
Multivariate OR‡ 8 y lag time | 1.00 (Reference) | 0.25 (0.07-0.90) | 0.29 (0.07-1.10) | 0.17 (0.04-0.71) | 0.01 |
↵*We tested for trends by modeling aMT6s concentrations continuously and calculating the Wald statistic.
↵†Simple conditional logistic regression model adjusting for the matching variables [year of birth, month and year of urine collection, and laboratory batch].
↵‡Multivariate conditional logistic regression models; relative risks were adjusted for the following breast cancer risk factors: BMI in six categories (≤21, 21.1-23, 23.1-25, 25.1-27, 27.1-30, >30), history of benign breast disease (yes/no), family history (mother or sister) of breast cancer (yes/no), smoking history (never, past, current), age at menarche in four categories (≤12, 13, 14, 15+), alcohol consumption per day in grams, three categories (none, ≤12, >12), years of oral contraceptive use (never, ≤1 y, >1 y), parity in three categories (nulliparous, 1-2, 3+ children), age at first birth in three categories (<20, 20-24, ≥25), and participant's educational status in years of schooling, three categories [≤5 y (elementary school), 8 y (superior education), >8 y].